Therapy Areas: Vaccines
DaVita Clinical Research study finds mRNA COVID-19 vaccines in dialysis patients clinically effective
29 November 2021 -

DaVita Clinical Research (DCR), a wholly owned subsidiary of kidney care services provider DaVita Inc (NYSE: DVA) and the research arm of DaVita, reported on Monday that its study has revealed that dialysis patients who received mRNA COVID-19 vaccines had a lower risk of COVID-19 diagnosis post-vaccination and were less likely to be hospitalised or die following breakthrough infection, compared to unvaccinated patients.

This study has been published online ahead of print by the Journal of the American Society of Nephrology.

Researchers evaluated electronic health records of 35,206 DaVita dialysis patients vaccinated with Pfizer/BioNTech or Moderna vaccines between 1 January and 25 February 2021, to assess COVID-19 vaccine effectiveness in this patient population. These patients were matched to unvaccinated controlled groups and followed over time to observe future COVID-19 infections and related clinical outcomes, the company said.

DCR added that its researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing COVID-19 infections, respectively. Among vaccinated dialysis patients, SARS-CoV-2 antibodies were also detected in rates similar to those seen in the broader Phase III clinical trials.



Related Headlines